Evidence map›Paper›PMID 37279466›Full record

ArticleACS sensors2023

Environmentally Resilient Microfluidic Point-of-Care Immunoassay Enables Rapid Diagnosis of Talaromycosis.

David S Kinnamon, Jacob T Heggestad, Jason Liu, Thu Nguyen, Vo Ly, Angus M Hucknall, Cassio M Fontes, Rhett J Britton, Jian-Piao Cai, Jasper Fuk-Woo Chan and 3 more

Open access · greenAbstract read
In one paragraph

Article in ACS sensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Development and Clinical Evaluation of a Novel Talaromyces marneffei Mp1p Lateral Flow Assay for Rapid Diagnosis of Talaromycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Recent Advances in the Diagnosis of Talaromycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 4 countries.

David S KinnamonDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0001-9463-6613
Jacob T HeggestadDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0001-5217-6735
Jason LiuDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States.
Thu NguyenDivision of Infectious Diseases and International Health, Duke University School of Medicine, Durham, North Carolina 27708, United States.
Vo LyHospital for Tropical Disease, Ho Chi Minh City 73009, Vietnam.
Angus M HucknallDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States.
Cassio M FontesDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0003-3157-478X
Rhett J BrittonDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States.
Jian-Piao CaiState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam 000000, Hong Kong.
Jasper Fuk-Woo ChanState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam 000000, Hong Kong.
Kwok-Yung YuenState Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam 000000, Hong Kong.
Thuy LeDivision of Infectious Diseases and International Health, Duke University School of Medicine, Durham, North Carolina 27708, United States.
Ashutosh ChilkotiDepartment of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0002-1569-2228
Duke University · USHainan Medical University · CNUniversity of Hong Kong · HKUniversity of Medicine and Pharmacy at Ho Chi Minh City · VN

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Susanna Naggie, GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
University Training Program in Biomolecular & Tissue EngineeringT32GM008555 · NIGMS · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 1994 to 2021
$8.1M
A Fully Integrated Point-of-Care Test for EbolaR01AI150888 · NIAID · DUKE UNIVERSITY · PI CHILKOTI, ASHUTOSH · 2020 to 2024
$3.4M
Development, Clinical Validation, and Readiness for Implementation of a Novel Mp1p D4 Poin Diagnosis of Talaromycosist of Care Test for RapidR01AI177098 · NIAID · DUKE UNIVERSITY · PI Ashutosh Chilkoti, Thuy Le · 2023 to 2026
$2.8M
Making an early diagnosis of talaromycosis - an approach to reduce morbidity and mortality in advanced HIV disease in Southeast AsiaR01AI143409 · NIAID · DUKE UNIVERSITY · PI LE, THUY · 2019 to 2024
$2.8M
University Training Program in Biomolecular and Tissue EngineeringT32GM144291 · NIGMS · DUKE UNIVERSITY · PI Charles A. Gersbach, Tatiana Segura · 2022 to 2026
$2.6M
Tropical Medicine Research Center for Talaromycosis in VietnamU01AI169358 · NIAID · DUKE UNIVERSITY · PI Thuy Le · 2022 to 2026
$2.5M
Smartphone Enabled Point-of-Care Detection of Serum Markers of Liver CancerUH3CA211232 · NCI · DUKE UNIVERSITY · PI CHAO, NELSON J., CHILKOTI, ASHUTOSH · 2019 to 2021
$1.9M
Multiplex point-of-care test for diagnosis, prognosis and serology of COVID19R01AI159992 · NIAID · DUKE UNIVERSITY · PI CHILKOTI, ASHUTOSH · 2021 to 2023
$1.5M
NCI NIH HHS UH3 CA211232NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI143409NIAID NIH HHS R01 AI150888NIAID NIH HHS R01 AI159992NIAID NIH HHS R01 AI177098NIAID NIH HHS U01 AI169358NIGMS NIH HHS T32 GM008555NIGMS NIH HHS T32 GM144291
6 · The paper itself

Abstract

Point-of-care tests (POCTs) are increasingly being used in field settings, particularly outdoors. The performance of current POCTs─most commonly the lateral flow immunoassay─can be adversely affected by ambient temperature and humidity. We developed a self-contained immunoassay platform─the D4 POCT─that can be conducted at the POC by integrating all reagents in a capillary-driven passive microfluidic cassette that minimizes user intervention. The assay can be imaged and analyzed on a portable fluorescence reader─the D4Scope─and provide quantitative outputs. Here, we systematically investigated the resilience of our D4 POCT to varied temperature and humidity and to physiologically diverse human whole blood samples that span a wide range of physiological hematocrit (30-65%). For all conditions, we showed that the platform maintained high sensitivity (0.05-0.41 ng/mL limits of detection). The platform also demonstrated good accuracy in reporting true analyte concentration across environmental extremes when compared to the manually operated format of the same test to detect a model analyte─ovalbumin. Additionally, we engineered an improved version of the microfluidic cassette that improved the ease-of-use of the device and shortened the time-to-result. We implemented this new cassette to create a rapid diagnostic test to detect talaromycosis infection in patients with advanced HIV disease at the POC, demonstrating comparable sensitivity and specificity to the laboratory test for the disease.

Indexed as

MicrofluidicsPoint-of-Care SystemsHumansImmunoassayMycosesPoint-of-Care Testingbiosensordiagnosticsimmunoassayinfectious diseasemicrofluidicspoint-of-care test

Identifiers

PMID37279466
PMCPMC10449026
OpenAlexW4379598311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.